Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980341 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
A Phase 1 study, sponsored by Daiichi Sankyo Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 182
- Enrollment target
NCT02980341 is a Phase 1 study that has completed, run by Daiichi Sankyo Co.. The registered enrollment target is 182 participants.
The verdict
NCT02980341, a Phase 1 study, has completed, sponsored by Daiichi Sankyo Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 182 participants
- Enrollment target
Study Summary
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer. The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.
Interventions
- DRUG Patritumab Deruxtecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2023-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02980341
The ClinicalTrials.gov registry entry for NCT02980341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patritumab Deruxtecan is the first listed.
NCT02980341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02980341 about?
NCT02980341 is a clinical study titled "Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer". This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer. The number of pati...
What is the current status of trial NCT02980341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 182 participants. The study started on 2016-11-28. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT02980341?
The interventions under investigation include: Patritumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT02980341?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.